BioSpace News Archive

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (FSE: A2JMZC) (“Khiron” or the “Company”), announces that its wholly owned subsidiary ZereniaTM Colombia has closed an unsecured revolving credit facility of CAD 580,0001 with a private financing company in Colombia.

Canada Diagnostic Centres, a leading provider of medical imaging services, announces the strategic acquisitions of both Guardian Radiology and The Ultrasound Centre.

Abivax SA (Euronext Paris:FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announced that its scientific abstract has been selected for a poster presentation at the 18th Congress of ECCO taking place on March 1-4, 2023, in Copenhagen, Denmark.

Peak Pharmaceuticals, Inc., announced that it will effect a 1-for-200 reverse stock split of its outstanding common stock.

LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT) announced that, as recently reported in The Journal of Clinical Investigation, PP2A, the pharmacologic target of LIXTE’s lead clinical compound, LB-100, when deficient, enhances the effects of immune checkpoint blockade of cancer in a mouse model by a previously unappreciated mechanism.

Madisonville Community College is one of 16 colleges that make up the Kentucky Community & Technical College System.

RxSight, Inc. announced that, in connection with its previously announced public offering of common stock, the underwriters exercised in full their option to purchase an additional 600,000 shares of RxSight’s common stock at a public offering price of $12.50 per share.

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022.

Biotricity Inc.(Nasdaq:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced its financial results and provided a business update for its third quarter of fiscal 2023 ended December 31, 2022.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended December 31, 2022, and other recent developments.